Pharmacotherapy considerations in patients with HIV and psychiatric disorders: Focus on antidepressants and antipsychotics

Annals of Pharmacotherapy

Volumn 47, Issue 1, 2013, Pages 75-89

  Hill, Lucas ^a   Lee, Kelly C ^b  

^a UCSD MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; EFAVIRENZ; ESCITALOPRAM; FLUOXETINE; FOSAMPRENAVIR PLUS RITONAVIR; ILOPERIDONE; INDINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; OLANZAPINE; PAROXETINE; PIMOZIDE; PLACEBO; PROTEINASE INHIBITOR; QUETIAPINE; RISPERIDONE; RITONAVIR; SAQUINAVIR; SERTRALINE; TESTOSTERONE; TIPRANAVIR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZIDOVUDINE; ZIPRASIDONE;

AREA UNDER THE CURVE; ARTICLE; BECK DEPRESSION INVENTORY; BIPOLAR DISORDER; CARDIOVASCULAR RISK; DELIRIUM; DEPRESSION; DIABETIC KETOACIDOSIS; DYSTHYMIA; FOOD AND DRUG ADMINISTRATION; HAMILTON SCALE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPODYSTROPHY; MAJOR DEPRESSION; OBSERVATIONAL STUDY; PANCREATITIS; PARANOIA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SEROTONIN SYNDROME; SOMATIZATION; SUICIDAL IDEATION;

ANTI-HIV AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; MENTAL DISORDERS;

EID: 84872976231     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R343     Document Type: Article

References (66)

1. Wagner GJ, Goggin K, Remien RH, et al. A closer look at depression and its relationship to HIV antiretroviral adherence, Ann Behav Med 2011;42(3):352-360.
2. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr 2011;58:181-187. doi: 10.1097/QAI.0b013e31822d490a
3. Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009;21:976-983. doi: 10.1080/09540120802657555
4. Watkins CC, Pieper AA, Treisman GJ. Safety considerations in drug treatment of depression in HIV-positive patients: an updated review. Drug Saf 2011;34:623-639.
5. Nel A, Kagee A. Common mental health problems and antiretroviral therapy adherence. AIDS Care 2011;23:1360-1365.doi: 10.1080/09540121.2011.565025
6. Vranceanu AM, Safren SA, Lu M, et al. The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV. AIDS Patient Care STDS 2008;22:313-321. doi: 10.1089/apc.2007.0069
7. Sumari-Deboer IM, Sprangers MA, Prins JM, Nieuwkerk PT. HIV stigma and depressive symptoms are related to adherence and virological response to antiretroviral treatment among immigrant and indigenous HIV infected patients. AIDS Behav 2012;16:1681-1689.doi: 10.1007/s10461-0110112-y
8. Blashill AJ, O'Cleirigh C, Mayer KH, Goshe BM, Safren SA. Body mass index, depression and sexual transmission risk behaviors among HIV-positive MSM. AIDS Behav 2012;16:2251-2256.doi: 10.1007/s10461-0110056-2
9. Nejad SH, Gandhi RT, Freudenreich O. Clozapine use in HIV-infected schizophrenia patients: a case-based discussion and review. Psychosomatics 2009;50:626-632. doi: 10.1176/appi.psy.50.6.626
10. Singh D, Goodkin K. Choice of antipsychotic in HIV-infected patients. J Clin Psychiatry 2007;68:479-480. doi: 10.4088/JCP.v68n0318
11. Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999;156:101-107.
12. Targ EF, Karasic DH, Diefenbach PN, Anderson DA, Bystritsky A, Fawzy FI. Structured group therapy and fluoxetine to treat depression in HIV-positive persons. Psychosomatics 1994;35:132-137.doi: 10.1016/S0033-3182(94)71786-2
13. Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry 1998;59:217-224.doi: 10.4088/JCP.v59n0502
14. Schwartz JA, McDaniel JS. Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study. Depress Anxiety 1999;9:704.doi: 10.1002/(SICI)1520-6394(1999)9:2<70::AID -DA4>3.0.CO;2-L
15. Grassi B, Gambini O, Garghentini G, Lazzarin A, Scarone S. Efficacy of paroxetine for the treatment of depression in the context of HIV infection. Pharmacopsychiatry 1997;30:70-71. doi: 10.1055/s-2007-979485
16. Elliott AJ, Uldall KK, Bergam K, Russo J, Claypoole K, Roy-Byrne PP. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry 1998;155:367-372.
17. Rabkin JG, Wagner G, Rabkin R. Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. J Clin Psychiatry 1994;55:433-439.
18. Currier MB, Molina G, Kato M. Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study. Psychosomatics 2004;45:210-216. doi: 10.1176/appi.psy.45.3.210
19. Rabkin JG, Rabkin R, Harrison W, Wagner G. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 1994;151:516-523.
20. Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007;69:1314-1321. doi: 10.1212/01.wnl.0000268487.78753.0f
21. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab 2000;85:60-65.doi: 10.1210/jc.85.1.60
22. Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Lin SH. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebocontrolled trial. J Clin Psychopharmacol 2004;24:379-385.
23. Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry 2006;163:59-66. doi: 10.1176/appi.ajp.163.1.59
24. Bradley M, McElhiney M, Rabkin J. DHEA and cognition in HIV-positive patients with non-major depression. Psychosomatics 2012;53:244-249. doi: 10.1016/j.psym.2011.08.005
25. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000;61:436-440.
26. Fernandez F, Levy JK, Samley HR, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry Med 1995;25:53-67. doi: 10.2190/16FH-9ECT-Y280-VV45
27. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231-237. doi: 10.1002/(SICI)1099-1611(199703)6:1<75::AID -PON259>3.0.CO;2-R.
28. Lera G, Zirulnik J. Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord 1999;14:128-131. doi: 10.1002/1531-8257(199901)14:1<128::AID -MDS1021>3.0.CO;2-J
29. Singh AN, Golledge H, Catalan J. Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. J Psychosom Res 1997;42:489-493. doi: 10.1016/S0022-3999(96)00373-X
30. Lodge P, Tanner M, McKeogh MM. Risperidone in the management of agitation in HIV dementia. Palliat Med 1998;12:206-207.doi: 10.1177/026921639801200310
31. Spiegel DR, Weller AL, Pennell K, Turner K. The successful treatment of mania due to acquired immunodeficiency syndrome using ziprasidone: a case series. J Neuropsychiatry Clin Neurosci 2010;22:111-114. doi: 10.1176/appi.neuropsych.22.1.111
32. Product information. Prozac (fluoxetine hydrochloride). Indianapolis, IN: Eli Lilly and Co., June 2011.
33. Product information. Paxil (paroxetine hydrochloride). Weston, FL: GlaxoSmithKline, July 2011.
34. DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001;15:1281-1285. doi: 10.1097/00002030-200107060-00010
35. Bertz R, Foit C, Chiu Y-L, et al. Multipledose kaletra (lopinavir/ritonavir) does not affect the pharmacokinetics of the CYP2D6 probe, desipramine (abstract 433-W). Presented at: 9th Conferences on Retroviruses and Opportunistic Infections. http://retroconferenceorg/2002/Abstract/13452.htm (accessed 2013 Jan 13). doi: 10.2165/00044011-200323100 00002
36. de Maat MM, Huitema AD, Mulder JW, et al. Drug interaction of fluvoxamine and fluoxetine with nevirapine in HIV-1-infected individuals. Clin Drug Investig 2003;23:629-637. doi: 10.1128/AAC.01243-06
37. van der Lee MJ, Blenke AA, Rongen GA, et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother 2007;51:4098-4104.doi: 10.1128/AAC.01243-06
38. Product information. Sustiva (efavirenz). Princeton, NJ: Bristol-Myers Squibb Co., June 2012.
39. Michaud V, Ogburn E, Thong N, et al. Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clin Pharmacol Ther 2012;91:475-482.doi: 10.1038/clpt.2011.249
40. Liu P, Foster G, LaBadie RR, Gutierrez MJ, Sharma A. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 2008;48:73-84.doi: 10.1177/0091270003251864
41. Product information. Celexa (citalopram hydrobromide). St. Louis, MO: Forest Pharmaceuticals, Inc, March 2002.
42. Product information. Lexapro (escitalopram oxalate). St. Louis, MO: Forest Pharmaceuticals, Inc, May 2011.
43. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003;25:1200-1210. doi: 10.1016/S0149-2918(03)80076-0
44. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003;43:414-422.doi: 10.1177/0091270009359524
45. Product information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, March 2012.
46. Product information. Effexor (venlafaxine hydrochloride). Philadelphia, PA: Wyeth Pharmaceuticals, Inc, November 2011.
47. Hesse LM, Greenblatt DJ, von Moltke LL, Court MH. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J Clin Pharmacol 2006;46: 567-576. doi: 10.1177/0091270006286981
48. Park J, Vousden M, Brittain C, et al. Dose-related reduction in bupropion plasma concentrations by ritonavir. J Clin Pharmacol 2010;50:1180-1187.
49. Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008;49:513-519.
50. Meyer JM, Marsh J, Simpson G. Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient. Biol Psychiatry 1998;44:7914. doi: 10.1016/S0006-3223(97)00552-0
51. Kelly DV, Beique LC, Bowmer MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 2002;36:827-830. doi: 10.1345/aph.1A335
52. Aung GL, O'Brien JG, Tien PG, Kawamoto LS. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother 2010;44:18504.doi: 10.1345/aph.1P139
53. Product information. Seroquel (quetiapine fumarate). Wilmington, DE: AstraZeneca Pharmaceuticals LLP, December 2011.
54. Product information. Geodon (ziprasidone HCl). New York: Pfizer, August 2008.
55. Product information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, April 2012.
56. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-69.doi: 10.1097/01.jcp.0000104913.75206.62
57. Product information. ORAP (pimozide). Sellersville, PA: Teva Pharmaceuticals USA, January 2008.
58. Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol 2002;22:366-370.doi: 10.1097/00004714-200208000-00006
59. Foster R, Olajide D, Everall IP. Antiretroviral therapy-induced psychosis: case report and brief review of the literature. HIV Med 2003;4:13944. doi: 10.1046/j.1468-1293.2003.00142.x
60. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenzand protease inhibitor- treated patients. HIV Clin Trials 2005;6:187-196.doi: 10.1310/92VR-FP24-J8GA-B49Q
61. Hriso E, Kuhn T, Masdeu JC, Grundman M. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 1991;148:1558-1561.
62. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24:S7-S14.doi: 10.1097/01.jcp.0000142282.62336.e9
63. Vergara-Rodriguez P, Vibhakar S, Watts J. Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness. Pharmacol Ther 2009;124:269-278. doi: 10.1016/j.pharmthera.2009.07.004
64. Magkos F, Mantzoros CS. Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment. Metabolism 2011;60:749-753. doi: 10.1016/j.metabol.2010.09.011
65. del Palacio M, Alvarez S, Munoz-Fernandez MA. HIV-1 infection and neurocognitive impairment in the current era. Rev Med Virol 2012;22: 3345. doi: 10.1002/rmv.711
66. Berger JR, Arendt G. HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 2000;14:214-221. doi: 10.1177/026988110001400304